Share on LinkedInShare on LinkedIn

ARTICLE · 17 SEPTEMBER 2015

IPR Reform Still Unresolved

The issue of IPRs has received a lot of media coverage recently, with Bloomberg News, BioWorld, and Law360, among others reporting on the drug-patent challenges brought by hedge fund manager Kyle Bass.

United StatesIntellectual Property

The issue of IPRs has received a lot of media coverage recently, with Bloomberg News, BioWorld, and Law360, among others reporting on the drug-patent challenges brought by hedge fund manager Kyle Bass. Nutter partner Lana Gladstein, who has extensive experience with the inter partes review (IPR) process, has been tapped as an expert source on the topic by several reporters for these and other stories. Bass has initiated nearly three dozen drug-patent challenges. In recent weeks The Patent Trial and Appeal Board (PTAB) denied trial institution of two petitions filed by Bass against two patents held by Acorda Therapeutics on its multiple sclerosis drug Ampyra and also denied institution on one of the two petitions filed by Bass against Biogen's multiple sclerosis drug Tecfidera. In the Biogen and Acorda cases, the companies argued that Bass is misusing the system to make money by undermining drug patents, however, neither panel addressed that issue.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from